Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.

Annals of the American Thoracic Society - 1 Feb 2020

Sergeev Valentine, Chou Frank Y, Lam Grace Y, Hamilton Christopher Michael, Wilcox Pearce G, Quon Bradley S

Abstract excerpt

The effects of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators on lung function, pulmonary exacerbations, and quality of life have been well documented. However, CF is a multiorgan disease, and therefore an evidence base is emerging on the systemic effects of CFTR modulators beyond the pulmonary system. This is of great clinical importance, as many of these studies provide proof of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzodioxoles

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Drug Combinations

Share to Quinolones

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 31661636
DOI: 10.1513/AnnalsATS.201909-671CME
PMCID: PMC6993798

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.PMID 31661636Read ↗

CFTR Modulators: Current Status and Evolving Knowledge.Semantic proximity Read ↗

Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients.Semantic proximity Read ↗

CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in FranceSemantic proximity Read ↗

Beyond the Lungs-Emerging Challenges in Adult Cystic Fibrosis Care.Semantic proximity Read ↗

Effect of CFTR Modulators on Anthropometric Parameters in Individuals with Cystic Fibrosis: An Evidence Analysis Center Systematic Review.Semantic proximity Read ↗

Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.Semantic proximity Read ↗

Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.Semantic proximity Read ↗

Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.Semantic proximity Read ↗

Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.Semantic proximity Read ↗

Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators.Semantic proximity Read ↗

Current state of CFTR modulators for treatment of Cystic Fibrosis.Semantic proximity Read ↗

Update on Cystic Fibrosis in Pediatric Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.